Rohto Pharmaceutical Co (4527) Stock Statistics & Valuation Metrics

Rohto Pharmaceutical Co has a market cap or net worth of JPY 625.90B. The enterprise value is JPY 531.68B.

Market Cap

JPY 625.90B

Enterprise Value

JPY 531.68B

Rohto Pharmaceutical Co has 236,178,310 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

236,178,310

Owned by Insiders

―

Owned by Institutions

19.61%

Rohto Pharmaceutical Co’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 7.61%.

Return on Equity (ROE)

0.11

Return on Assets (ROA)

0.07

Return on Invested Capital (ROIC)

7.61%

Return on Capital Employed (ROCE)

0.11

Revenue Per Employee

36.99M

Profits Per Employee

3.69M

Employee Count

9,292

Asset Turnover

0.71

Inventory Turnover

2.45

The current PE Ratio of Rohto Pharmaceutical Co is 18.54. Rohto Pharmaceutical Co’s PEG ratio is -6.06.

PE Ratio

18.54

PS Ratio

1.74

PB Ratio

1.98

Price to FCF

0.00

Price to Operating Cash Flow

0.00

PEG Ratio

-6.06

In the last 12 months, Rohto Pharmaceutical Co had revenue of 343.73B and earned 34.25B in profits. Earnings per share was 151.56.

Revenue

343.73B

Gross Profit

182.96B

Operating Income

40.71B

Pretax Income

46.82B

Net Income

34.25B

EBITDA

65.48B

Earnings Per Share (EPS)

151.56

In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.

Operating Cash Flow

0

Free Cash Flow

0

Free Cash Flow per Share

0.00

Rohto Pharmaceutical Co pays an annual dividend of JPY 25.00, resulting in a dividend yield of 1.85%

Dividend Per Share

JPY 25.00

Dividend Yield

1.85%

Payout Ratio

30.35%

Free Cash Flow Yield

0.00%

Earnings Yield

5.31%

Beta

0.47

52-Week Price Change

14.37%

50-Day Moving Average

2808.47

200-Day Moving Average

2527.12

Relative Strength Index (RSI)

43.02

Average Volume (3m)

1.14M

Rohto Pharmaceutical Co upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

Sep 29, 2026

Rohto Pharmaceutical Co as a current ratio of 2.04, with Debt / Equity ratio of 19.96%

Current Ratio

2.04

Quick Ratio

1.48

Debt to Market Cap

0.10

Net Debt to EBITDA

-0.41

Interest Coverage Ratio

31.70

In the past 12 months, Rohto Pharmaceutical Co has paid 12.40B in taxes.

Income Tax

12.40B

Effective Tax Rate

0.26

Rohto Pharmaceutical Co EV to EBITDA ratio is 9.31, with an EV/FCF ratio of 0.00.

EV to Sales

1.69

EV to EBITDA

9.31

EV to Free Cash Flow

0.00

EV to Operating Cash Flow

0.00

Rohto Pharmaceutical Co has JPY 84.77B in cash and marketable securities with JPY 58.10B in debt, giving a net cash position of JPY 26.67B billion.

Cash & Marketable Securities

JPY 84.77B

Total Debt

JPY 58.10B

Net Cash

JPY 26.67B

Net Cash Per Share

JPY 112.92

Tangible Book Value Per Share

JPY 1,081.71

Gross margin is 55.56%, with operating margin of 12.10%, and net profit margin of 9.38%.

Gross Margin

55.56%

Operating Margin

12.10%

Pretax Margin

13.17%

Net Profit Margin

9.38%

EBITDA Margin

18.16%

EBIT Margin

13.12%

The average price target for Rohto Pharmaceutical Co is JPY 3,350.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

JPY 3,350.00

Price Target Upside

21.29% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

9.67%

EPS Growth Forecast

-2.92%

Smart Score

―

AI Score

78.25